IceCure Medical Ltd. (Nasdaq: ICCM) has filed a 510(k) submission with the FDA for clearance of its next-generation single probe cryoablation system, the XSense™ System…
April 02, 2024
NeuroBo Completes Enrollment in Liver Disease Trial
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment of patients in Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety of…
April 01, 2024
Fractyl Health Receives Investigational Device Exemption from FDA for Revita Weight Loss Procedure
Metabolic therapeutics company, Fractyl Health (Nasdaq: GUTS) has received FDA approval of a pivotal Investigational Device Exemption (IDE) to study its lead product candidate, Revita’s,…
Innovent Biologics (HKEX: 01801) has dosed the first participant with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial for…
Molecular genetics diagnostics company, Mainz Biomed N.V. (Nasdaq: MYNZ) presented its ColoAlert® cancer screening innovation at the 39th UDH Congress in Fellbach, Germany this month….
March 28, 2024
PRISM Emerging Psychedelics Spotlight: Cybin, Inc.
Psychedelic-based therapeutics company, Cybin, Inc. (NYSE American: CYBN) has achieved an impressive number of key milestones this month, and the investment community is taking note….
NeuroOne Medical Technologies (Nasdaq: NMTC) has initiated a limited commercial launch of its OneRF™ Ablation System, a stereoelectroencephalogram (sEEG)-guided tool used in neurosurgery to record…
Enveric Biosciences (Nasdaq: ENVB) has provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31,…
Shares in Viking Therapeutics (Nasdaq: VKTX) surged on Tuesday after the company announced positive results from its Phase 1 clinical trial evaluating its oral tablet…
Medical technology company, Neuronetics, Inc. (Nasdaq: STIM), has received clearance from the FDA for its NeuroStar Advanced Therapy for use as an adjunct for the…
March 25, 2024
Seelos Misses Endpoints in Blow to ALS Community
Biopharmaceutical company, Seelos Therapeutics (Nasdaq: SEEL) has missed primary and secondary endpoints in its Phase 2/3 HEALEY ALS Platform trial of SLS-005 in a blow…
Mental health company, BrainsWay Ltd. (Nasdaq: BWAY) has received an order for 18 of its Deep Transcranial Magnetic Stimulation (Deep TMS™) systems from Katie’s Way…